Related Experiment Video
Updated: Aug 18, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Long-term combination therapy with aspirin and clopidogrel
C R Kumana1, Giselle Cheung, I J Lauder
1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
Insights
Combining aspirin and clopidogrel offers no overall advantage over single anti-platelet therapy for preventing cardiovascular events, despite potential bleeding risks. This analysis reviewed CURE and MATCH trial data for high-risk patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Aspirin and clopidogrel are antiplatelet agents used to prevent atherothrombotic events.
- Previous studies like CURE and MATCH explored their combined use.
Purpose of the Study:
- To evaluate the absolute benefits and harms of combined aspirin and clopidogrel therapy versus monotherapy.
- To determine the number needed to treat (NNT) per year for adverse cardiovascular outcomes and major bleeding.
Main Methods:
- Analysis of data from the CURE and MATCH clinical trials.
- Calculation of NNT per year for primary composite cardiovascular outcomes and major bleeding events.
Main Results:
- Combination therapy prevented one adverse cardiovascular outcome in 35-204 treated patients annually.
- Approximately 1 in 63 patients on combination therapy experienced major bleeding annually.
- No significant overall advantage was found for combination therapy over monotherapy.
Conclusions:
- Current evidence suggests no net benefit of combining aspirin and clopidogrel compared to using either agent alone.
- The risk of major bleeding associated with combination therapy may outweigh its benefits.
Abstract:
The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies. To assess the overall absolute beneficial and/or harmful impact of aspirin and clopidogrel combination therapy compared with monotherapy with either drug, we analyzed the results from both trials in terms of number needed to treat per year. Treating between 35 and 204 at-risk patients for 1 year with combination therapy appeared to prevent 1 patient from experiencing an adverse primary cardiovascular outcome; whereas, about 1 in 63 such patients appeared liable to major bleeding during that period. We determined that the evidence to date indicates no overall advantage for combination therapy with anti-platelet drugs in preference to monotherapy.
More Related Videos
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 3, 2013
06:59Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care